PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
-57.23%
Revenue decline while Biotechnology median is 0.00%. Seth Klarman would investigate if market share loss is temporary.
No Data
No Data available this quarter, please select a different quarter.
-57.23%
Gross profit decline while Biotechnology median is 0.00%. Seth Klarman would investigate competitive position.
No Data
No Data available this quarter, please select a different quarter.
-15.08%
R&D reduction while Biotechnology median is 3.08%. Seth Klarman would investigate competitive implications.
-0.47%
G&A reduction while Biotechnology median is 0.00%. Seth Klarman would investigate efficiency gains.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-10.89%
Operating expenses reduction while Biotechnology median is 6.82%. Seth Klarman would investigate advantages.
-10.89%
Total costs reduction while Biotechnology median is 7.81%. Seth Klarman would investigate advantages.
No Data
No Data available this quarter, please select a different quarter.
3.20%
D&A growth exceeding 1.5x Biotechnology median of 1.97%. Jim Chanos would check for overinvestment.
5.74%
EBITDA growth while Biotechnology declines. Peter Lynch would examine advantages.
-120.42%
EBITDA margin decline while Biotechnology median is 0.00%. Seth Klarman would investigate causes.
5.53%
Operating income growth while Biotechnology declines. Peter Lynch would examine advantages.
-120.91%
Operating margin decline while Biotechnology median is 0.00%. Seth Klarman would investigate causes.
3.85%
Other expenses change of 3.85% versus flat Biotechnology. Walter Schloss would verify control.
5.62%
Pre-tax income growth while Biotechnology declines. Peter Lynch would examine advantages.
-120.69%
Pre-tax margin decline while Biotechnology median is 0.00%. Seth Klarman would investigate causes.
No Data
No Data available this quarter, please select a different quarter.
5.62%
Net income growth while Biotechnology declines. Peter Lynch would examine advantages.
-120.69%
Net margin decline while Biotechnology median is 0.00%. Seth Klarman would investigate causes.
13.79%
EPS change of 13.79% versus flat Biotechnology. Walter Schloss would verify quality.
13.79%
Diluted EPS change of 13.79% versus flat Biotechnology. Walter Schloss would verify quality.
10.10%
Share count reduction below 50% of Biotechnology median of 0.44%. Jim Chanos would check for issues.
10.10%
Diluted share reduction below 50% of Biotechnology median of 0.40%. Jim Chanos would check for issues.